{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:09:21Z","timestamp":1779167361140,"version":"3.51.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the factors influencing the glucose-lowering efficacy of polyethylene glycol loxenatide (PEG-Loxe) added to diet, exercise, and existing glucose-lowering therapies in patients with poorly controlled type 2 diabetes mellitus (T2DM) after 12 weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter prospective cohort study with a pre-post intervention design, based on the FreeStyle Libre flash glucose monitoring (FGM) system, enrolled T2DM patients with inadequate glycemic control (HbA\n                      <jats:sub>1c &amp;gt;<\/jats:sub>\n                      7.5%) despite stable treatment (diet, exercise, and medication) for at least 8 weeks. PEG-Loxe (0.2 mg once weekly) was added to their original treatment regimen for 12 weeks. Demographic and clinical data were collected. Standardized meal tests were performed before and after treatment to measure glucose, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , insulin, C-peptide, and glucagon. Glycemic profiles, including 24-hour mean blood glucose (MBG), glucose variability (SDBG, CV), time in range (TIR), time above range (TAR), and time below range (TBR), were assessed using the hospital version of the Abbott FreeStyle Libre FGM system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 500 initially enrolled patients, 246 patients were included in the final analysis. Baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      was 8.74% \u00b1\u00a01.07%. After 12 weeks of PEG-Loxe add-on therapy, 39.6% of patients achieved HbA\n                      <jats:sub>1c &amp;lt;<\/jats:sub>\n                      6.5%, 63.3% achieved HbA\n                      <jats:sub>1c &amp;lt;<\/jats:sub>\n                      7.0%, and 77.12% attained TIR &amp;gt;70%. Significant reductions were observed across multiple parameters. Fasting blood glucose (FBG), postprandial blood glucose (PBG), MBG, TAR, and SDBG were significantly reduced (all P&amp;lt;0.05). Concurrently, TIR, insulin levels, C-peptide levels, and insulin resistance (as measured by HOMA-IR) improved, while 2-hour postprandial glucagon (2h-PGlu) decreased. No significant change in TBR was detected. Correlation analysis revealed that TIR improvement was associated with a shorter diabetes duration and higher baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      . Furthermore, PEG-Loxe treatment significantly improved cardiometabolic parameters and liver enzymes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PEG-Loxe significantly improved glycemic control in Chinese patients with T2DM who were overweight or obese. Patients who were younger, had a shorter duration of diabetes, and presented with higher baseline glucose levels appeared to derive greater benefit from the therapy. Beyond glycemic control, PEG-Loxe might also show additional benefits across multiple cardiometabolic indices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>www.clinicaltrials.gov<\/jats:uri>\n                      , identifier NCT05611684.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1810786","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:22:51Z","timestamp":1779164571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system"],"prefix":"10.3389","volume":"17","author":[{"given":"Liye","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Nanjing Lishui People\u2019s Hospital, Zhongda Hospital Lishui Branch, Southeast University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Nanjing Lishui People\u2019s Hospital, Zhongda Hospital Lishui Branch, Southeast University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rengna","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocen","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2025.5956","article-title":"Diagnosis and treatment of type 2 diabetes in adults: A review","volume":"334","author":"Kalyani","year":"2025","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.22208","article-title":"Prevalence and treatment of diabetes in China, 2013-2018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(24)00251-2","article-title":"Diabetes in China part 2: prevention, challenges, and progress","volume":"9","author":"Xu","year":"2024","journal-title":"Lancet Public Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1106868","article-title":"Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial","volume":"14","author":"Cai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1235639","article-title":"Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12933-025-02915-1","article-title":"Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes","volume":"24","author":"S\u00f8rensen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p736","article-title":"RCTs and real world evidence are complementary, not alternatives","volume":"381","author":"Morales","year":"2023","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110568","article-title":"Clinical expert consensus on the assessment and protection of pancreatic islet beta-cell function in type 2 diabetes mellitus","volume":"197","author":"Zhu","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1370594","article-title":"Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on \"time in range\" in patients with type 2 diabetes","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15045","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study","volume":"25","author":"Mohammedi","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2021.06.008","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark\/Sweden multicentre, prospective, observational study","volume":"15","author":"Rajamand Ekberg","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0030","article-title":"Safety and effectiveness of dulaglutide in the treatment of type 2 diabetes mellitus: A Korean real-world post-marketing study","volume":"48","author":"Han","year":"2024","journal-title":"Diabetes Metab J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1347684","article-title":"Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i5.731","article-title":"Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges","volume":"16","author":"Xie","year":"2024","journal-title":"World J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70094","article-title":"Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (2020)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1810786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:22:51Z","timestamp":1779164571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1810786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":23,"alternative-id":["10.3389\/fendo.2026.1810786"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1810786","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1810786"}}